Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate PTC Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding PTC Therapeutics, Inc.’s stock price such as:

• PTC Therapeutics, Inc.’s current stock price and volume
• Why PTC Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PTCT from analysts
• PTCT’s stock price momentum as measured by its relative strength

About PTC Therapeutics, Inc. (PTCT)

Before we jump into PTC Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Want to learn more about PTC Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about PTC Therapeutics, Inc..

PTC Therapeutics, Inc.’s Stock Price as of Market Close

As of August 07, 2026, 1:57 PM, CST, PTC Therapeutics, Inc.’s stock price was $72.450.

PTC Therapeutics, Inc. is up 2.26% from its previous closing price of $70.850.

During the last market session, PTC Therapeutics, Inc.’s stock traded between $70.950 and $72.550. Currently, there are approximately 83.01 million shares outstanding for PTC Therapeutics, Inc..

PTC Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

PTC Therapeutics, Inc. Stock Price History

PTC Therapeutics, Inc.’s (PTCT) price is currently up 6.53% so far this month.

During the month of August, PTC Therapeutics, Inc.’s stock price has reached a high of $72.550 and a low of $66.070.

Over the last year, PTC Therapeutics, Inc. has hit prices as high as $90.870 and as low as $43.175. Year to date, PTC Therapeutics, Inc.’s stock is down 4.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused PTC Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 06, 2026, there was 1 analyst who downgraded PTC Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate PTC Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on PTC Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

PTC Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about PTC Therapeutics, Inc. (PTCT) by visiting AAII Stock Evaluator.

Relative Price Strength of PTC Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 06, 2026, PTC Therapeutics, Inc. has a weighted four-quarter relative price strength of 4.35%, which translates to a Momentum Score of 69 and is considered to be Strong.

Want to learn more about how PTC Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

PTC Therapeutics, Inc. Stock Price: Bottom Line

As of August 7, 2026, PTC Therapeutics, Inc.’s stock price is $72.450, which is up 2.26% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like PTC Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.